Changes to the Code
S. 2345 · Short on Competition Act · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
21 U.S.C. § 356c Discontinuance or interruption in the production of life-saving drugs
2 changes the bill asks for here, 2 carried out
- Carried out:
by redesignating subsections (h), (i), and (j) as subsections (i), (j), and (k) respectively; and
- Carried out:
by inserting after subsection (g) the following:
(h) Temporary importation authority.— (1) In general.— If, based on notifications described in subsection (a) or any other relevant information, the Secretary concludes that there is, or is likely to be, a drug shortage of a drug described in subsection (a), except as provided …
§ 356c(g)–(k)
Start of § 356c to (g) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (g)(1) | (1) | (1) | ||
| prioritize and expedite the review of a supplement to a new drug application submitted under section 355(b) of this title, an abbreviated new drug application submitted under section 355(j) of this title, or a supplement to such an application submitted under section 355(j) of this title, that could help mitigate or prevent such shortage; or | prioritize and expedite the review of a supplement to a new drug application submitted under section 355(b) of this title, an abbreviated new drug application submitted under section 355(j) of this title, or a supplement to such an application submitted under section 355(j) of this title, that could help mitigate or prevent such shortage; or | |||
| (g)(2) | (2) | (2) | ||
| prioritize and expedite an inspection or reinspection of an establishment that could help mitigate or prevent such drug shortage. | prioritize and expedite an inspection or reinspection of an establishment that could help mitigate or prevent such drug shortage. | |||
| (h) | (h) [inserted: Temporary importation authority.—] | |||
| (h)(1) | (1) [inserted: In general.—] | |||
| [inserted: If, based on notifications described in subsection (a) or any other relevant information, the Secretary concludes that there is, or is likely to be, a drug shortage of a drug described in subsection (a), except as provided in paragraph (3), the Secretary shall authorize importation of such drug for a period of up to 3 years if—] | ||||
| (h)(1)(A) | (A) [inserted: ] | |||
| [inserted: the drug is a drug subject to section 503(b)(1), including a combination product whose primary mode of action is that of a drug as determined under section 503(g)(1)(D)(i), other than a drug described in subparagraphs (A) through (F) of section 804(a)(3);] | ||||
| (h)(1)(B) | (B) [inserted: ] | |||
| [inserted: the drug is authorized to be lawfully marketed in one or more of the countries included in the list under section 802(b)(1);] | ||||
| (h)(1)(C) | (C) [inserted: ] | |||
| [inserted: the imported drug has the same active ingredient as the drug for which there is a shortage with respect to manufacturers in the United States;] | ||||
| (h)(1)(D) | (D) [inserted: ] | |||
| [inserted: the manufacturer certifies to the Secretary that it intends to seek approval of the drug under section 505(j); and] | ||||
| (h)(1)(E) | (E) [inserted: ] | |||
| [inserted: an importer (as defined in section 804(a)) files with the Secretary information—] | ||||
| (h)(1)(E)(i) | (i) [inserted: ] | |||
| [inserted: attesting that the requirements under subparagraphs (A) through (D) are satisfied;] | ||||
| (h)(1)(E)(ii) | (ii) [inserted: ] | |||
| [inserted: identifying the drug the importer proposes to import and the manufacturer from whom the importer proposes to import such drug; and] | ||||
| (h)(1)(E)(iii) | (iii) [inserted: ] | |||
| [inserted: requesting authority to import the drug.] | ||||
| (h)(2) | (2) [inserted: Beginning date of importation.—] | |||
| [inserted: Except as provided in paragraph (3), if all of the conditions under paragraph (1) are met, the Secretary shall authorize importation of a drug in accordance with such paragraph beginning not later than 60 days after receipt of the information under paragraph (1)(E).] | ||||
| (h)(3) | (3) [inserted: Discretionary denial of importation.—] | |||
| [inserted: The Secretary may deny importation of a drug otherwise qualified for importation under paragraph (1) if the Secretary determines that—] | ||||
| (h)(3)(A) | (A) [inserted: ] | |||
| [inserted: the drug is not safe and effective;] | ||||
| (h)(3)(B) | (B) [inserted: ] | |||
| [inserted: the drug is used in conjunction with a device for which there is no reasonable assurance of safety and effectiveness; or] | ||||
| (h)(3)(C) | (C) [inserted: ] | |||
| [inserted: the authorization to market the drug in one or more of the countries included in the list under section 802(b)(1) has been rescinded or withdrawn because of any concern relating to the safety or effectiveness of the drug.] | ||||
| (h)(4) | (4) [inserted: Termination of authority.—] | |||
| [inserted: The authority to import a drug pursuant to paragraph (1) shall terminate after 3 years, or when the drug shortage no longer applies, whichever occurs first.] | ||||
| (i) | [inserted: (i)] Definitions | |||
| For purposes of this section— | For purposes of this section— | |||
| (i)(1) | (1) | (1) | ||
| the term “drug”— | the term “drug”— | |||
| (i)(1)(A) | (A) | (A) | ||
| means a drug (as defined in section 321(g) of this title) that is intended for human use and that is subject to section 353(b)(1) of this title; and | means a drug (as defined in section 321(g) of this title) that is intended for human use and that is subject to section 353(b)(1) of this title; and | |||
| (i)(1)(B) | (B) | (B) | ||
| does not include biological products (as defined in section 262 of title 42), unless otherwise provided by the Secretary in the regulations promulgated under subsection (i); | does not include biological products (as defined in section 262 of title 42), unless otherwise provided by the Secretary in the regulations promulgated under subsection (i); | |||
| (i)(2) | (2) | (2) | ||
| the term “drug shortage” or “shortage”, with respect to a drug, means a period of time when the demand or projected demand for the drug within the United States exceeds the supply of the drug; and | the term “drug shortage” or “shortage”, with respect to a drug, means a period of time when the demand or projected demand for the drug within the United States exceeds the supply of the drug; and | |||
| (i)(3) | (3) | (3) | ||
| the term “meaningful disruption”— | the term “meaningful disruption”— | |||
| (i)(3)(A) | (A) | (A) | ||
| means a change in production that is reasonably likely to lead to a reduction in the supply of a drug by a manufacturer that is more than negligible and affects the ability of the manufacturer to fill orders or meet expected demand for its product; and | means a change in production that is reasonably likely to lead to a reduction in the supply of a drug by a manufacturer that is more than negligible and affects the ability of the manufacturer to fill orders or meet expected demand for its product; and | |||
| (i)(3)(B) | (B) | (B) | ||
| does not include interruptions in manufacturing due to matters such as routine maintenance or insignificant changes in manufacturing so long as the manufacturer expects to resume operations in a short period of time. | does not include interruptions in manufacturing due to matters such as routine maintenance or insignificant changes in manufacturing so long as the manufacturer expects to resume operations in a short period of time. | |||
| (j) | [inserted: (j)] Regulations | |||
| (j)(1) | (1) In general | (1) In general | ||
| Not later than 18 months after July 9, 2012, the Secretary shall adopt a final regulation implementing this section. | Not later than 18 months after July 9, 2012, the Secretary shall adopt a final regulation implementing this section. | |||
| (j)(2) | (2) Contents | (2) Contents | ||
| Such regulation shall define, for purposes of this section, the terms “life-supporting”, “life-sustaining”, and “intended for use in the prevention or treatment of a debilitating disease or condition”. | Such regulation shall define, for purposes of this section, the terms “life-supporting”, “life-sustaining”, and “intended for use in the prevention or treatment of a debilitating disease or condition”. | |||
| (j)(3) | (3) Inclusion of biological products | (3) Inclusion of biological products | ||
| (j)(3)(A) | (A) In general | (A) In general | ||
| The Secretary may by regulation apply this section to biological products (as defined in section 262 of title 42), including plasma products derived from human plasma protein and their recombinant analogs, if the Secretary determines such inclusion would benefit the public health. Such regulation shall take into account any supply reporting programs and shall aim to reduce duplicative notification. | The Secretary may by regulation apply this section to biological products (as defined in section 262 of title 42), including plasma products derived from human plasma protein and their recombinant analogs, if the Secretary determines such inclusion would benefit the public health. Such regulation shall take into account any supply reporting programs and shall aim to reduce duplicative notification. | |||
| (j)(3)(B) | (B) Rule for vaccines | (B) Rule for vaccines | ||
| If the Secretary applies this section to vaccines pursuant to subparagraph (A), the Secretary shall— | If the Secretary applies this section to vaccines pursuant to subparagraph (A), the Secretary shall— | |||
| (j)(3)(B)(i) | (i) | (i) | ||
| consider whether the notification requirement under subsection (a) may be satisfied by submitting a notification to the Centers for Disease Control and Prevention under the vaccine shortage notification program of such Centers; and | consider whether the notification requirement under subsection (a) may be satisfied by submitting a notification to the Centers for Disease Control and Prevention under the vaccine shortage notification program of such Centers; and | |||
| (j)(3)(B)(ii) | (ii) | (ii) | ||
| explain the determination made by the Secretary under clause (i) in the regulation. | explain the determination made by the Secretary under clause (i) in the regulation. | |||
| (j)(4) | (4) Procedure | (4) Procedure | ||
| In promulgating a regulation implementing this section, the Secretary shall— | In promulgating a regulation implementing this section, the Secretary shall— | |||
| (j)(4)(A) | (A) | (A) | ||
| issue a notice of proposed rulemaking that includes the proposed regulation; | issue a notice of proposed rulemaking that includes the proposed regulation; | |||
| (j)(4)(B) | (B) | (B) | ||
| provide a period of not less than 60 days for comments on the proposed regulation; and | provide a period of not less than 60 days for comments on the proposed regulation; and | |||
| (j)(4)(C) | (C) | (C) | ||
| publish the final regulation not less than 30 days before the regulation’s effective date. | publish the final regulation not less than 30 days before the regulation’s effective date. | |||
| (j)(5) | (5) Restrictions | (5) Restrictions | ||
| Notwithstanding any other provision of Federal law, in implementing this section, the Secretary shall only promulgate regulations as described in paragraph (4). | Notwithstanding any other provision of Federal law, in implementing this section, the Secretary shall only promulgate regulations as described in paragraph (4). | |||
| (k) | [inserted: (k)] Risk management plans | |||
| Each manufacturer of a drug described in subsection (a) or of any active pharmaceutical ingredient or any associated medical device used for preparation or administration included in the drug, shall develop, maintain, and implement, as appropriate, a redundancy risk management plan that identifies and evaluates risks to the supply of the drug, as applicable, for each establishment in which such drug or active pharmaceutical ingredient of such drug is manufactured. A risk management plan under this section shall be subject to inspection and copying by the Secretary pursuant to an inspection or a request under section 374(a)(4) of this title. | Each manufacturer of a drug described in subsection (a) or of any active pharmaceutical ingredient or any associated medical device used for preparation or administration included in the drug, shall develop, maintain, and implement, as appropriate, a redundancy risk management plan that identifies and evaluates risks to the supply of the drug, as applicable, for each establishment in which such drug or active pharmaceutical ingredient of such drug is manufactured. A risk management plan under this section shall be subject to inspection and copying by the Secretary pursuant to an inspection or a request under section 374(a)(4) of this title. | |||
21 U.S.C. § 356c–1 Annual reporting on drug shortages
3 changes the bill asks for here, 3 carried out
- Carried out:
in clause (i), by striking
; and
and inserting;
; - Carried out:
in clause (ii), by adding
and
after the semicolon;
and - Carried out:
by inserting after clause (ii) the following:
(iii) the number of drugs authorized for temporary importation under section 506C(h);.
§ 356c–1(a)Annual reports to Congress(5)–(7)
Start of § 356c–1 to (a)(5)(A) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (5)(B) | (B) | (B) | ||
| in the list under subparagraph (A), includes— | in the list under subparagraph (A), includes— | |||
| (5)(B)(i) | (i) | (i) | ||
| the number of applications and supplements for which the Secretary expedited review under section 356c(g)(1) of this title during such calendar year; | the number of applications and supplements for which the Secretary expedited review under section 356c(g)(1) of this title during such calendar year; | |||
| (5)(B)(ii) | (ii) | (ii) | ||
| the number of establishment inspections or reinspections that the Secretary expedited under section 356c(g)(2) of this title during such calendar year; | the number of establishment inspections or reinspections that the Secretary expedited under section 356c(g)(2) of this title during such calendar year;[inserted: and] | |||
| (5)(B)(iii) | (iii) [inserted: ] | |||
| [inserted: the number of drugs authorized for temporary importation under section 506C(h);] | ||||
| (6) | (6) | (6) | ||
| describes the coordination between the Food and Drug Administration and the Drug Enforcement Administration on efforts to prevent or alleviate drug shortages; | describes the coordination between the Food and Drug Administration and the Drug Enforcement Administration on efforts to prevent or alleviate drug shortages; | |||
| (7) | (7) | (7) | ||
| identifies the number of and describes the instances in which the Food and Drug Administration exercised regulatory flexibility and discretion to prevent or alleviate a drug shortage; | identifies the number of and describes the instances in which the Food and Drug Administration exercised regulatory flexibility and discretion to prevent or alleviate a drug shortage; | |||
Rest of § 356c–1 unchanged